未登录

H

Helena Domin

Polish Academy of Sciences

H指数:21

被引数:978

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

NS-398-induced membrane stiffening as a biophysical factor affecting memory-related processes

Biochemical and Biophysical Research Communications

IF2.2

2026-01-050

PRE

Cinnarizine, a Calcium Channel Blocker, Partially Prevents the Striatal Dopamine Decline and Loss of Nigral Dopamine Neurons in the Lactacystin-Induced Rat Model of Parkinson’s Disease

桂利嗪（Cinnarizine），一种钙通道阻滞剂，部分预防了乳清酸诱导的帕金森病大鼠模型中纹状体多巴胺的下降和黑质多巴胺能神经元的丢失。

International Journal of Molecular Sciences 2025, Vol. 26, Page 8833

IF4.9

2025-09-210

OAAI

mGlu4R, mGlu7R, and mGlu8R allosteric modulation for treating acute and chronic neurodegenerative disorders

PHARMACOLOGICAL REPORTS

IF3.8

2024-09-301

OAAI

The diverse role of corticotropin-releasing factor (CRF) and its CRF1 and CRF2 receptors under pathophysiological conditions: Insights into stress/ anxiety, depression, and brain injury processes

促肾上腺皮质激素释放因子 (CRF) 及其CRF1和CRF2受体在病理生理条件下的不同作用: 对压力/焦虑，抑郁和脑损伤过程的见解

NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

IF7.9

2024-08-012

PRE

Spectroscopic characterization and in vitro studies of biological activity of bradykinin derivatives

SCIENTIFIC REPORTS

IF3.9

2022-11-083

OAAI

Group III metabotropic glutamate receptors as promising targets for neuroprotective therapy: Particular emphasis on the role of mGlu4 and mGlu7 receptors

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

IF2.5

2022-09-0114

PRE

Neuropeptide Y Y2 and Y5 receptors as potential targets for neuroprotective and antidepressant therapies: Evidence from preclinical studies

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

IF3.9

2021-12-0114

PRE

Application of Alanine Scanning to Determination of Amino Acids Essential for Peptide Adsorption at the Solid/Solution Interface and Binding to the Receptor: Surface-Enhanced Raman/Infrared Spectroscopy versus Bioactivity Assays

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-06-109

OAAI

Characterization of the Brain Penetrant Neuropeptide Y Y2 Receptor Antagonist SF-11

ACS CHEMICAL NEUROSCIENCE

IF3.9

2019-06-198

PREAI

Neuroprotective effect of the group III mGlu receptor agonist ACPT-I after ischemic stroke in rats with essential hypertension

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

IF3.9

2018-06-0117

PREAI

Polarization effect in tip-enhanced infrared nanospectroscopy studies of the selective Y5 receptor antagonist Lu AA33810

IF9

2018-04-0414

OAAI

Monitoring the Interfacial Behavior of Selective Y5 Receptor Antagonist on Colloidal Gold Nanoparticle Surfaces: Surface-Enhanced Vibrational Spectroscopy Studies

JOURNAL OF PHYSICAL CHEMISTRY C

IF3.2

2017-08-0215

PREAI

SERS characterization of neuropeptide Y and its C-terminal fragments deposited onto colloidal gold nanoparticle surface

COLLOIDS AND SURFACES B-BIOINTERFACES

IF5.6

2017-01-014

PREAI

Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence

PSYCHOPHARMACOLOGY

IF3.3

2016-12-1420

OAAI

ACPT-I, a group III mGlu receptor agonist, reduces infarction and behavioral deficit in normotensive and spontaneously hypertensive rats subjected to transient focal cerebral ischemia

PHARMACOLOGICAL REPORTS

IF3.8

2015-09-010

PREAI

Neuroprotective effects of the allosteric agonist of metabotropic glutamate receptor 7 AMN082 on oxygen-glucose deprivation- and kainate-induced neuronal cell death

NEUROCHEMISTRY INTERNATIONAL

IF4

2015-09-0124

PREAI

Neuropeptide Y and its C-terminal fragments acting on Y2 receptor: Raman and SERS spectroscopy studies

JOURNAL OF COLLOID AND INTERFACE SCIENCE

IF9.7

2015-01-0115

PREAI

Stereological estimation of the substantia nigra neurons in 6-ODHA-lesioned rats receiving L-DOPA and the nitric oxide donor molsidomine

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2011-09-010

PREAI

Cinnarizine, a calcium channel antagonist, attenuates changes of parkinsonian-type induced in rat by the proteasome inhibitor lactacystin

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2011-09-010

PREAI

Anxiolytic-like activity of MGS0039, a selective group II mGlu receptor antagonist, is serotonin- and GABA-dependent

PHARMACOLOGICAL REPORTS

IF3.8

2011-07-0127

PREAI